2025年6月起,国内心血管植介入领军企业乐普医疗陆续公告聚乳酸面部填充剂、注射用透明质酸钠溶液、注射用交联透明质酸钠凝胶三款产品正式获得国家Ⅲ类医疗器械注册证,标志着公司正式进入医美领域。2025年10月11日,乐普医疗携旗下医美管线,在北京与美团举行签约仪式,双方正式达成战略合作。从左至右依次为:美团医药健康医美及美容上游负责人陈军与乐普医疗董事会秘书江维娜“心血管植介入专家”的医美新旅程...
Source Link2025年6月起,国内心血管植介入领军企业乐普医疗陆续公告聚乳酸面部填充剂、注射用透明质酸钠溶液、注射用交联透明质酸钠凝胶三款产品正式获得国家Ⅲ类医疗器械注册证,标志着公司正式进入医美领域。2025年10月11日,乐普医疗携旗下医美管线,在北京与美团举行签约仪式,双方正式达成战略合作。从左至右依次为:美团医药健康医美及美容上游负责人陈军与乐普医疗董事会秘书江维娜“心血管植介入专家”的医美新旅程...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.